SI2307409T1 - Pirolopiridini kot kinazni inhibitorji - Google Patents

Pirolopiridini kot kinazni inhibitorji

Info

Publication number
SI2307409T1
SI2307409T1 SI200931284T SI200931284T SI2307409T1 SI 2307409 T1 SI2307409 T1 SI 2307409T1 SI 200931284 T SI200931284 T SI 200931284T SI 200931284 T SI200931284 T SI 200931284T SI 2307409 T1 SI2307409 T1 SI 2307409T1
Authority
SI
Slovenia
Prior art keywords
pyrrolopyridines
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
SI200931284T
Other languages
English (en)
Slovenian (sl)
Inventor
Huerou Yvan Le
James F. Blake
Indrani W. Gunwardana
Peter J. Mohr
Eli M. Wallace
Bin Wang
Mark Chicarelli
Michael Lyon
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2307409(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of SI2307409T1 publication Critical patent/SI2307409T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200931284T 2008-05-13 2009-05-13 Pirolopiridini kot kinazni inhibitorji SI2307409T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5292608P 2008-05-13 2008-05-13
PCT/US2009/043691 WO2009140320A1 (en) 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors
EP09747404.3A EP2307409B1 (en) 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
SI2307409T1 true SI2307409T1 (sl) 2015-11-30

Family

ID=40810786

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931284T SI2307409T1 (sl) 2008-05-13 2009-05-13 Pirolopiridini kot kinazni inhibitorji

Country Status (30)

Country Link
US (6) US8178131B2 (enExample)
EP (2) EP2990407B1 (enExample)
JP (2) JP5703212B2 (enExample)
KR (2) KR101643426B1 (enExample)
CN (3) CN104926810B (enExample)
AR (1) AR071717A1 (enExample)
AU (1) AU2009246402B2 (enExample)
BR (1) BRPI0913580B8 (enExample)
CA (1) CA2724262C (enExample)
CL (1) CL2009001152A1 (enExample)
CO (1) CO6321244A2 (enExample)
CR (1) CR11803A (enExample)
CY (1) CY1116692T1 (enExample)
DK (1) DK2307409T3 (enExample)
ES (1) ES2552643T3 (enExample)
HK (1) HK1219950A1 (enExample)
HR (1) HRP20151018T1 (enExample)
HU (1) HUE026160T2 (enExample)
IL (1) IL209258A (enExample)
MX (1) MX2010012449A (enExample)
NZ (1) NZ589318A (enExample)
PH (1) PH12013501779B1 (enExample)
PL (1) PL2307409T3 (enExample)
PT (1) PT2307409E (enExample)
RS (1) RS54358B1 (enExample)
RU (1) RU2517194C2 (enExample)
SI (1) SI2307409T1 (enExample)
TW (2) TWI554512B (enExample)
UA (1) UA111933C2 (enExample)
WO (1) WO2009140320A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841304B2 (en) 2008-01-08 2014-09-23 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
JP5608098B2 (ja) 2008-01-09 2014-10-15 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害薬としてのピラゾロピリジン
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−3−イルカーバメート化合物の光学分割方法およびその中間体
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
BRPI1013920A2 (pt) * 2009-04-11 2016-04-05 Array Biopharma Inc inibidores de ponto de checagem de quinase 1 para potencializar agentes de danificação de dna
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2485589A4 (en) * 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
CN103119045B (zh) 2010-08-20 2016-02-17 和记黄埔医药(上海)有限公司 吡咯并嘧啶化合物及其用途
ES2621857T3 (es) 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
CN103492377B (zh) 2011-02-25 2016-04-20 阵列生物制药公司 作为pim激酶抑制剂的三唑并吡啶化合物
WO2012148775A1 (en) 2011-04-29 2012-11-01 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
RU2635359C2 (ru) 2012-04-23 2017-11-13 Дженентек Инк. Промежуточные химические соединения и способы получения соединений
CN105764502A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群及其类似物及衍生物的治疗益处的组合方法
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
KR102325163B1 (ko) 2013-08-22 2021-11-11 제넨테크, 인크. 화합물의 제조 방법
CN105722838B (zh) 2013-09-25 2017-10-24 沃泰克斯药物股份有限公司 磷脂酰肌醇3‑激酶‑γ的选择性抑制剂
MX385778B (es) 2014-04-04 2025-03-18 Del Mar Pharmaceuticals Uso de dianhidrogalactitol y análogos o derivados del mismo para tratar cáncer de células no pequeñas del pulmón y cáncer de ovario.
TW201613919A (en) 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
WO2017003090A1 (ko) 2015-06-30 2017-01-05 서울바이오시스 주식회사 Uv led가 적용된 포충기
KR102850604B1 (ko) 2015-11-04 2025-08-27 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 암 치료하는 방법
EP3394064A1 (en) * 2015-12-22 2018-10-31 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
PT3468966T (pt) 2016-06-10 2020-11-10 Vitae Pharmaceuticals Llc Inibidores da interação menina-mll
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
WO2019236884A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2020010092A1 (en) * 2018-07-03 2020-01-09 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种(3s,4r)-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种(3r,4s)-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
WO2020132045A1 (en) 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ifm Due有限公司 用於治療與sting活性相關之病況的化合物及組合物
JP2023540673A (ja) 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物
EP4274824A1 (en) 2021-01-08 2023-11-15 IFM Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
AU2022274325A1 (en) 2021-05-14 2023-10-05 Syndax Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
EP4384503A1 (en) 2021-08-10 2024-06-19 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN119798252A (zh) * 2023-10-09 2025-04-11 中国石油化工股份有限公司 一种制备n邻位-酰基取代的含氮杂环化合物及其缩胺合铁(ii)配合物的方法
WO2025260014A1 (en) * 2024-06-14 2025-12-18 Tenvie Therapeutics, Inc. Compounds, compositions, and methods

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0723545B1 (en) 1993-10-14 2002-05-08 Abbott Laboratories Quinolizinone type compounds
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CA2399791A1 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
MXPA02010222A (es) 2000-04-18 2003-05-23 Agouron Pharma Pirazoles para inhibir proteina cinasa.
AU2002336462A1 (en) 2001-09-06 2003-03-24 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US6797825B2 (en) * 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003250539A1 (en) 2002-08-07 2004-02-25 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
EP1613625A1 (en) 2003-03-14 2006-01-11 AstraZeneca AB Novel fused triazolones and the uses thereof
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
WO2005103050A2 (en) * 2004-04-02 2005-11-03 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
TWI380816B (zh) * 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-12(il-12)生成之二鹽抑制劑
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US20090275570A1 (en) 2005-04-06 2009-11-05 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
CA2609126A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
AU2006285915B2 (en) * 2005-08-30 2011-02-24 Asahi Kasei Pharma Corporation Sulfonamide compound
CA2627623C (en) * 2005-10-06 2014-04-22 Schering Corporation Methods for inhibiting protein kinases
AR056206A1 (es) 2005-10-06 2007-09-26 Schering Corp Pirazolpirimidinas como inhibidores de protein quinasas
LT2455382T (lt) 2005-12-13 2017-02-10 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir prolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
EP3421471B1 (en) * 2006-04-25 2021-05-26 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US20090082370A1 (en) 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
EP2016077A2 (en) 2006-04-25 2009-01-21 Astex Therapeutics Limited Pharmaceutical compounds
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
CA2679659C (en) 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
EP2170886A1 (en) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
EP2217611B1 (en) 2007-11-07 2013-07-31 Merck Sharp & Dohme Corp. Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
US8841304B2 (en) * 2008-01-08 2014-09-23 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
JP5608098B2 (ja) * 2008-01-09 2014-10-15 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害薬としてのピラゾロピリジン
AR071717A1 (es) * 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US20140221370A1 (en) 2010-07-09 2014-08-07 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
ES2621857T3 (es) 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1

Also Published As

Publication number Publication date
NZ589318A (en) 2011-06-30
IL209258A (en) 2017-01-31
EP2990407A1 (en) 2016-03-02
CN102089307A (zh) 2011-06-08
CN102089307B (zh) 2015-07-01
US20150322061A1 (en) 2015-11-12
CR11803A (es) 2011-02-11
KR20140093266A (ko) 2014-07-25
TW201002707A (en) 2010-01-16
PL2307409T3 (pl) 2016-01-29
RS54358B1 (sr) 2016-04-28
PH12013501779A1 (en) 2014-08-27
CL2009001152A1 (es) 2009-10-16
US20130045286A1 (en) 2013-02-21
US8178131B2 (en) 2012-05-15
PH12013501779B1 (en) 2019-02-13
AU2009246402A1 (en) 2009-11-19
ES2552643T3 (es) 2015-12-01
US20140100369A1 (en) 2014-04-10
JP2011520896A (ja) 2011-07-21
CY1116692T1 (el) 2017-03-15
US20140243520A1 (en) 2014-08-28
DK2307409T3 (en) 2015-09-21
EP2307409A1 (en) 2011-04-13
TWI458727B (zh) 2014-11-01
WO2009140320A1 (en) 2009-11-19
BRPI0913580B8 (pt) 2021-05-25
HK1219950A1 (en) 2017-04-21
US9969727B2 (en) 2018-05-15
AR071717A1 (es) 2010-07-07
CA2724262A1 (en) 2009-11-19
MX2010012449A (es) 2011-05-25
JP5703212B2 (ja) 2015-04-15
JP2015098482A (ja) 2015-05-28
CA2724262C (en) 2017-08-15
UA111933C2 (uk) 2016-07-11
CN104926810A (zh) 2015-09-23
US9365568B2 (en) 2016-06-14
AU2009246402B2 (en) 2013-05-23
CN104926810B (zh) 2019-02-19
PT2307409E (pt) 2015-11-04
HUE026160T2 (en) 2016-05-30
EP2990407B1 (en) 2019-10-16
BRPI0913580B1 (pt) 2020-03-10
HRP20151018T1 (hr) 2015-10-23
KR101643426B1 (ko) 2016-07-27
CO6321244A2 (es) 2011-09-20
US20110070317A1 (en) 2011-03-24
TWI554512B (zh) 2016-10-21
BRPI0913580A2 (pt) 2015-10-20
IL209258A0 (en) 2011-01-31
CN109942575A (zh) 2019-06-28
TW201529573A (zh) 2015-08-01
US8758830B2 (en) 2014-06-24
RU2517194C2 (ru) 2014-05-27
RU2010150786A (ru) 2012-06-20
KR20110008102A (ko) 2011-01-25
US8545897B2 (en) 2013-10-01
EP2307409B1 (en) 2015-08-12
US20160368916A1 (en) 2016-12-22
KR101657856B1 (ko) 2016-09-19
US8981085B2 (en) 2015-03-17
HK1152035A1 (en) 2012-02-17

Similar Documents

Publication Publication Date Title
IL209258A0 (en) Pyrrolopyridines as kinase inhibitors
IL257083A (en) History of phosphorus as kinase inhibitors
ZA201102423B (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
IL209729A0 (en) Novel phenylpyrazinones as kinase inhibitors
IL206358A0 (en) Pyrrolopyrazine kinase inhibitors
PL2334677T3 (pl) Związki triazolopirydynowe jako inhibitory kinazy PIM
ZA201204246B (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
SG175195A1 (en) Imidazopyrazines for use as kinase inhibitors
ZA201100344B (en) Pyrimidine derivatives as kinase inhibitors
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
IL210573A0 (en) Compounds as kinase inhibitors
PL2231642T3 (pl) Pirymidyny jako inhibitory kinazy
IL206394A0 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
ZA201008878B (en) Naphthyridiniones as aurora kinase inhibitors
GB0914726D0 (en) Kinase inhibitors
ZA201004903B (en) Pyrrolopyrazine kinase inhibitors